A Two-arm Multi-stage (TAMS) Seamless Phase II/III Randomised Trial of Nivolumab in Combination With TACE/TAE for Patients With Intermediate Stage HCC
Latest Information Update: 05 Mar 2025
At a glance
- Drugs Nivolumab (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- Acronyms TACE-3
Most Recent Events
- 26 Feb 2025 Planned End Date changed from 1 Jun 2026 to 30 Jun 2026.
- 26 Feb 2025 Planned primary completion date changed from 1 Jun 2025 to 1 Aug 2025.
- 26 Feb 2025 Status changed from recruiting to suspended because analysis meant the study should close to recruitment.